Evidence on GLP-1 Use and Pregnancy Outcomes Limited prospective human data exist on GLP-1 use during pregnancy
To request a FREE 2- week trial subscription , please signup
Modern obesity pharmacotherapies are not simply weight-loss agents
Nevertheless, Competent Authorities perform an in-market control: they systematically monitor that the products available on the EU market are compliant (Article 22 of the EU Cosmetics Regulation)
People notice mild to moderate skin looseness in specific areas such as the face, neck, arms, or abdomen
Muscle and heart disease: including muscle weakness, cardiomyopathy (myocardial hypertrophy or dilation), and arrhythmias.Nervous system effects: may manifest as brain damage, seizures, intellectual disability, ataxia, etc